Panorama from the oncolytic virotherapy summit

Molecular Therapy

Volumn 21, Issue 10, 2013, Pages 1814-1818

  Pol, Jonathan G ^a   Marguerie, Monique ^b   Arulanandam, Rozanne ^b   Bell, John C ^b   Lichty, Brian D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNX 2401; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IFOSFAMIDE; IRINOTECAN; MELANOMA ANTIGEN 3; MITOXANTRONE; NTX 010; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; PROTEIN SERINE THREONINE KINASE INHIBITOR; PVS RIPO; SHORT HAIRPIN RNA; SORAFENIB; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VCN 01; VIRUS HEMAGGLUTININ; VOCIMAGENE AMIRETROREPVEC;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; BREAST TUMOR; CANADA; CARCINOMATOUS PERITONITIS; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; IMMUNOREGULATION; LIVER CELL CARCINOMA; LUNG TUMOR; MELANOMA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SARCOMA; SOLID TUMOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; WORKSHOP;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84885001986     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.207     Document Type: Conference Paper

References (39)

1. Sheridan, C (2013). Amgen announces oncolytic virus shrinks tumors. Nat Biotechnol 31: 471-472.
2. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
3. Gujar, SA, Marcato, P, Pan, D and Lee, PW (2010). Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther 9: 2924-2933.
4. Gujar, SA, Pan, D, Marcato, P, Garant, KA and Lee, PW (2011). Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther 19: 797-804.
5. Gujar, S, Dielschneider, R, Clements, D, Helson, E, Shmulevitz, M, Marcato, P et al. (2013). Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Mol Ther 21: 338-347.
6. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
7. Tai, LH, de Souza, CT, Bélanger, S, Ly, L, Alkayyal, AA, Zhang, J et al. (2013). Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res 73: 97-107.
8. Tai, LH, Zhang, J, Scott, KJ, Tanese de Souza, C, Alkayyal, AA, Ananth, AA et al. (2013). Perioperative influenza vaccination reduces post-operative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin Cancer Res; e-pub ahead of print 30 August 2013.
9. Zhang, W, Fulci, G, Wakimoto, H, Cheema, TA, Buhrman, JS, Jeyaretna, DS et al. (2013). Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 15: 591-599.
10. Fu, X, Rivera, A, Tao, L and Zhang, X (2012). Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity. Mol Ther 20: 1871-1881.
11. Paglino, JC and van den Pol, AN (2011). Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol 85: 9346-9358.
12. Le Boeuf, F, Diallo, JS, McCart, JA, Thorne, S, Falls, T, Stanford, M et al. (2010). Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18: 888-895.
13. Bridle, BW, Stephenson, KB, Boudreau, JE, Koshy, S, Kazdhan, N, Pullenayegum, E et al. (2010). Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18: 1430-1439.
14. Pulido, J, Kottke, T, Thompson, J, Galivo, F, Wongthida, P, Diaz, RM et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 30: 337-343.
15. Ottolino-Perry, K, Tang N, Head R, Ng, C, Arulanandam, R, Angarita, FA et al. (2013). Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis. Int J Cancer; e-pub ahead of print 29 August 2013.
16. Chan, WM, Bartee, EC, Moreb, JS, Dower, K, Connor, JH and McFadden, G (2013). Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol 87: 4445-4460.
17. Ganesh, S, Gonzalez-Edick, M, Gibbons, D, Van Roey, M and Jooss, K (2008). Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res 14: 3933-3941.
18. Wang, KS, Kuhn, RJ, Strauss, EG, Ou, S and Strauss, JH (1992). High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 66: 4992-5001.
19. Berno, V, Porrini, D, Castiglioni, F, Campiglio, M, Casalini, P, Pupa, SM et al. (2005). The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocr Relat Cancer 12: 393-406.
20. Shafren, DR, Au, GG, Nguyen, T, Newcombe, NG, Haley, ES, Beagley, L et al. (2004). Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res;10(Pt 1): 53-60.
21. Finkelshtein, D, Werman, A, Novick, D, Barak, S and Rubinstein, M (2013). LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci USA 110: 7306-7311.
22. Ayala-Breton, C, Barber, GN, Russell, SJ and Peng, KW (2012). Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 23: 484-491.
23. Muik, A, Kneiske, I, Werbizki, M, Wilflingseder, D, Giroglou, T, Ebert, O et al. (2011). Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol 85: 5679-5684.
24. Frame, FM and Maitland, NJ (2011). Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv Exp Med Biol 720: 105-118.
25. Bach, P, Abel, T, Hoffmann, C, Gal, Z, Braun, G, Voelker, I et al. (2013). Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 73: 865-874.
26. Moerdyk-Schauwecker, M, Shah, NR, Murphy, AM, Hastie, E, Mukherjee, P and Grdzelishvili, VZ (2013). Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 436: 221-234.
27. Noyce, RS, Bondre, DG, Ha, MN, Lin, LT, Sisson, G, Tsao, MS et al. (2011). Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 7: e1002240.
28. Miest, TS, Frenzke, M and Cattaneo, R (2013). Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy. Mol Ther; e-pub ahead of print 5 August 2013.
29. Poirier, JT, Dobromilskaya, I, Moriarty, WF, Peacock, CD, Hann, CL and Rudin, CM (2013). Selective tropism of Seneca valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst 105: 1059-1065.
30. Altman, JK, Glaser, H, Sassano, A, Joshi, S, Ueda, T, Watanabe-Fukunaga, R et al. (2010). Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol 78: 778-784.
31. Zhao, Y, Shen, S, Guo, J, Chen, H, Greenblatt, DY, Kleeff, J et al. (2006). Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res 136: 325-335.
32. Bartee, E, Chan, WS, Moreb, JS, Cogle, CR and McFadden, G (2012). Selective purging of human multiple myeloma cells from autologous stem cell transplant grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant 18: 1540-1551.
33. Rahman, MM, Madlambayan, GJ, Cogle, CR and Mc- Fadden, G (2010). Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with myxoma virus. Cytokine Growth Factor Rev 21: 169-175.
34. Kim, M, Madlambayan, GJ, Rahman, MM, Smallwood, SE, Meacham, AM, Hosaka, K et al. (2009). Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 23: 2313-2317.
35. Madlambayan, GJ, Bartee, E, Kim, M, Rahman, MM, Meacham, A, Scott, EW et al. (2012). Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res 36: 619-624.
36. Bartee, E, Meacham, A, Wise, E, Cogle, CR and Mc- Fadden, G (2012). Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. PLoS One 7: e43298.
37. Belin, LJ, Ady, JW, Lewis, C, Marano, D, Gholami, S, Mojica, K et al. (2013). An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma. Surgery 154: 486-495.
38. Li, H, Nakashima, H, Decklever, TD, Nace, RA and Russell, SJ (2013). HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther 20: 478-485.
39. Li, H, Peng, KW and Russell, SJ (2012). Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum Gene Ther 23: 295-301.